Skip to content

Advertisement

Cardiovascular Diabetology

Open Access

Correction to: Updates on cardiovascular outcome trials in diabetes

  • Oliver Schnell1Email author,
  • Lars Rydén2,
  • Eberhard Standl1,
  • Antonio Ceriello3, 4 and
  • on behalf of the D&CVD EASD Study Group
Cardiovascular Diabetology201716:150

https://doi.org/10.1186/s12933-017-0633-4

Received: 7 November 2017

Accepted: 7 November 2017

Published: 15 November 2017

The original article was published in Cardiovascular Diabetology 2017 16:128

Correction to: Cardiovasc Diabetol (2017) 16:128 https://doi.org/10.1186/s12933-017-0610-y

Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below), as the original version contained a mistake.
Table 4

Comparison of outcome results from terminated CVOTs in comparison to placebo

 

SAVOR-TIMI53 [1, 2]

EXAMINE [3, 4]

TECOS [5]

ELIXA [6]

EMPA-REG OUTCOME [7]

LEADER [8]

Class

HR (95% CI)

Class

HR (95% CI)

Class

HR (95% CI)

Class

HR (95% CI)

Class

HR (95% CI)

Class

HR (95% CI)

p value

p value

p value

p value

p value

p value

Cardiovascular endpoints

 Primary composite MACE

CV death, MI, or stroke

1.00 (0.89–1.12)

0.99

CV death, MI, or stroke

0.96 (≤ 1.16)

0.32

CV death, MI, UA, or stroke

0.98 (0.89–1.08)

0.65

CV death, MI, UA, or stroke

1.02 (0.89–1.17)

0.81

CV death, MI, or stroke

0.86 (0.74–0.99)

0.04a

CV death, MI, or stroke

0.87 (0.78–0.97)

0.01

 Cardiovascular death

Primary endpoint

1.03 (0.87–1.22)

0.72

Primary endpoint

0.79 (0.60–1.04)

0.10

Secondary endpoint

1.03 (0.89–1.19)

0.71

Primary endpoint

0.98 (0.78–1.22)

0.85

Primary endpoint

0.62 (0.49–0.77)

< 0.001

Primary endpoint

0.78 (0.66–0.93)

0.007

 Myocardial infarction

Primary endpoint

0.95 (0.80–1.12)

0.52

Primary endpoint

1.08 (0.88–1.33)

0.47

Secondary endpoint

0.95 (0.81–1.11)

0.49

Primary endpoint

1.03 (0.87–1.22)

0.71

Primary endpoint

0.87 (0.70–1.09)

0.23

Primary endpoint

0.86 (0.73–1.00)

0.046

 Stroke

Primary endpoint

1.11 (0.88–1.39)

0.38

Primary endpoint

0.91 (0.55–1.50)

0.71

Secondary endpoint

0.97 (0.79–1.19)

0.76

Primary endpoint

1.12 (0.79–1.58)

0.54

Primary endpoint

1.18 (0.89–1.56)

0.26

Primary endpoint

0.86 (0.71–1.06)

0.16

 Hospitalization for unstable angina

Secondary endpoint

1.19 (0.89–1.60)

0.24

Secondary endpoint

0.90 (0.60–1.37)

0.632

Secondary endpoint

0.90 (0.70–1.16)

0.42

Primary endpoint

1.11 (0.47–2.62)

0.81

Secondary endpoint

0.99 (0.74–1.34)

0.97

Extended

primary endpoint

0.98 (0.76–1.26)

0.87

 Hospitalization for heart failure

Secondary endpoint

1.27 (1.07–1.51)

0.007

Extended primary endpoint

1.19 (0.90–1.58)

0.220

Secondary endpoint

1.00 (0.83–1.20)

0.98

Secondary endpoint

0.96 (0.75–1.23)

0.75

Secondary endpoint

0.65 (0.50–0.85)

0.002

Extended

primary endpoint

0.87 (0.73–1.05)

0.14

 

Event rate (%) active group

 

Event rate (%) active group

 

Event rate (%) active group

 

Event rate (%) active group

 

Event rate (%) active group

 

Event rate (%) active group

 

 Primary composite MACE

7.3

 

11.3

 

9.6

 

13.4

 

10.5

 

13.0

 
 

No. (%)

p value

 

No. (%)

p value

 

No. (%)

p value

 

No. (%)

p value

 

No. (%)

p value

 

No. (%)

p value

 

Non-cardiovascular endpoints

 Renal event

5.8

0.04

 

0.9

0.88

 

1.4

 

1.6

 

5.2

 

5.7

0.003

 

 Acute pancreatitis

0.3

0.77

 

0.4

0.5

 

0.3

0.07

 

0.2

 

0.3b

 

0.4

0.44

 

 Hypoglycemia events

15.3

< 0.001

 

6.7

0.74

 

2.2

0.33

 

16.6

0.14

 

2.8

 

2.4

0.02

 
 

SUSTAIN 6 [9]

EXSCEL [10]

DEVOTE [11]

CANVAS program [12]

ACE [13]

Class

HR (95% CI)

p value

Class

HR (95% CI)

p value

Class

HR (95% CI)

p value

Class

HR (95% CI)

p value

Class

HR (95% CI)

p value

Cardiovascular endpoints

 Primary composite MACE

CV death, MI, or stroke

0.74 (0.58–0.95)

0.02a

CV death, MI or stroke

0.91 (0.83–1.00)

0.06a

CV death, MI or stroke

0.91 (0.78–1.06)

< 0.001

CV death, MI or stroke

0.86 (0.75–0.97)

0.02a

CV death, MI, stroke, UA and HF

0.98 (0.86–1.11)

0.73

 Cardiovascular death

Primary endpoint

0.98 (0.65–1.48)

0.92

Secondary endpoint

0.88 (0.76–1.02)

Primary endpoint

0.96 (0.76–1.21)

0.71

Primary endpoint

0.87 (0.72–1.06)

Secondary endpoint

0.89 (0.71–1.11)

0.29

 Myocardial infarction

Primary endpoint

0.74 (0.51–1.08)

0.12

Secondary endpoint

0.97 (0.85–1.10)

Primary endpoint

0.85 (0.68–1.06)

0.15

Primary endpoint

0.89 (0.73–1.09)

Secondary endpoint

1.12 (0.87–1.46)

0.38

 Stroke

Primary endpoint

0.61 (0.38–0.99)

0.04

Secondary endpoint

0.85 (0.70–1.03)

Primary endpoint

0.90 (0.65–1.23)

0.50

Primary endpoint

0.87 (0.69–1.09)

Secondary endpoint

0.97 (0.70–1.33)

0.83

 Hospitalization for unstable angina

Extended primary endpoint

0.82 (0.47–1.44)

0.49

Primary endpoint

0.95 (0.68–1.31)

0.74

Secondary endpoint

1.02 (0.82–1.26)

0.87

 Hospitalization for heart failure

Extended primary endpoint

1.11 (0.77–1.61)

0.57

Secondary endpoint

0.94 (0.78–1.13)

Secondary endpoint

0.67 (0.52–0.87)

Secondary endpoint

0.89 (0.63–1.24)

0.48

 

Event rate (%) active group

Event rate (%) active group

Event rate (%) active group

Event rate (%) active group

Event rate (%) active group

 Primary composite MACE

6.6

11.4

8.5

26.9d

14.4

 

No. (%)

p value

No. (%)

p value

No. (%)

p value

No. (%)

p value

No. (%)

p value

Non-cardiovascular endpoints

 Renal event

3.9

55 (0.7)

3.8

19.7d

0.32

 Acute pancreatitis

0.55

26 (0.4)

0.5d

0.63

 Hypoglycemia events

22.4c

247 (3.4)

4.9

< 0.001a

56.0d

0.20

54 (2)

0.95

aSuperiority test

bAverage across all age ranges

cSevere hypoglycaemia as defined by ADA

dNumber of participants per 1000 patient-years

The original article has been corrected.

References
  1. 1.

    Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145–53.

     
  2. 2.

    Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

     
  3. 3.

    White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

     
  4. 4.

    Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.

     
  5. 5.

    Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–42.

     
  6. 6.

    Pfeffer MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

     
  7. 7.

    Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

     
  8. 8.

    Marso SP, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–22

     
  9. 9.

    Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

     
  10. 10.

    Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

     
  11. 11.

    Marso SP, et al. Efficacy and safety of degludec versus glargine in Type 2 diabetes. N Engl J Med. 2017;377(8):723–32.

     
  12. 12.

    Neal B, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57.

     
  13. 13.

    Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213-8587(17):30309–1.

     

Notes

Declarations

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Forschergruppe Diabetes e. V., Munich, Germany
(2)
Cardiology Unit, Department of Medicine K2, Karolinska Institute, Stockholm, Sweden
(3)
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación, Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
(4)
Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Milan, Italy

Reference

  1. Schnell O, Rydén L, Standl E, Ceriello A, on behalf of the D&CVD EASD Study Group. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16:128. https://doi.org/10.1186/s12933-017-0610-y.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement